ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1660

Skeletal Myopathy in Systemic Sclerosis Associates with Higher Disease Burden and Mortality

Julie Paik1, Caoilfhionn Connolly1, Fredrick Wigley1 and Laura Hummers2, 1Johns Hopkins University, Baltimore, MD, 2Johns Hopkins Univerisity, Baltimore, MD

Meeting: ACR Convergence 2022

Keywords: Mortality, Myopathies, Myositis, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 14, 2022

Title: Abstracts: Systemic Sclerosis and Related Disorders – Clinical II: Clinical Phenotypes

Session Type: Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: Skeletal myopathy in systemic sclerosis (SSc) is poorly understood. The etiology of myopathy in SSc is heterogeneous and can result from an inflammation, disuse, malnutrition, or other neuromuscular diseases. The purpose of this study was to determine the clinical phenotype and risk of mortality of SSc patients with and without a myopathy.

Methods: To understand the clinical impact of skeletal myopathy in SSc, we utilized a large prospective scleroderma cohort to identify patients with and without myopathy. Key clinical variables included SSc disease subtype, age of SSc onset, disease duration, right ventricular systolic pressure on echocardiogram, pulmonary function tests, ejection fraction (EF) on echocardiogram, and Medsger severity scores. The presence of myopathy was defined as any physician reported history of myositis, or a patient having elevated creatine kinase, myopathic findings on electromyography, muscle edema on magnetic resonance imaging (MRI), or myopathic findings on muscle biopsy. Commercially available scleroderma specific autoantibodies were also obtained.

Clinical characteristics were compared between patients with and without myopathy using student’s t-tests and Fischer’s exact test as appropriate. Cox proportional hazards analyzes were performed to determine the relationship between myopathy and survival. All statistical analyses were performed using Stata, version 17; all statistical tests were 2-sided, and a p-value < 0.05 was considered statistically significant.

Results: 678 (17%) of 3,923 patients in the SSc cohort had a skeletal myopathy. When compared to those without a myopathy, those with myopathy were more commonly of the diffuse subtype (60.5% vs 32.5%, p < 0.0001), African-American (30.4% vs 13.9%, p< 0.0001), and with shorter disease duration at first visit (4.52 + 6.2 years vs 6.5 + 8.0 years, p< 0.00001). Patients with a myopathy also had more severe cardiopulmonary disease (see Table1).

Of the 678 patients with a myopathy, 213 (31%) had completed an EMG of which 92(43%) had an irritable myopathy. 170 of 678 (25%) patients had completed muscle MRI of which 130(76.5%) demonstrated muscle edema. 167 of 678 (24.6%) had undergone a muscle biopsy; inflammation (41.3%) was the most prevalent individual histologic feature followed by necrosis (36.9%), and fibrosis (30.7%).

Myopathy was associated with an increased risk of mortality in univariate Cox regression analyses (HR 1.59 [1.40-1.81],p=< 0.0001) (Figure 1). Older age at SSc onset, diffuse subtype, and more severe lung disease was also associated with increased risk of death. In multivariate Cox proportional regression analyses, myopathy had an independent risk of death even after controlling for other confounders (adjusted HR 1.69 [1.44-1.99], p=< 0.0001).

Conclusion: Skeletal myopathy in SSc is associated with higher overall disease burden and risk for mortality. Further studies are needed to determine whether specific myopathic features such as histologic diagnosis also contribute to poor outcomes.

Supporting image 1

Supporting image 2

Kaplan Meier survival estimates comparing scleroderma patients who have myopathy versus those who do not have myopathy and time till death


Disclosures: J. Paik, Pfizer Inc, Kezar Inc, Roivant, Argenx, Alexion Inc; C. Connolly, None; F. Wigley, None; L. Hummers, Boehringer-Ingelheim, Corbus Pharmaceuticals, Cumberland Pharmaceuticals, Kadmon Corporation, Medpace, CSL Behring, Mitsubishi Tanabe, Horizon Pharmaceuticals.

To cite this abstract in AMA style:

Paik J, Connolly C, Wigley F, Hummers L. Skeletal Myopathy in Systemic Sclerosis Associates with Higher Disease Burden and Mortality [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/skeletal-myopathy-in-systemic-sclerosis-associates-with-higher-disease-burden-and-mortality/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/skeletal-myopathy-in-systemic-sclerosis-associates-with-higher-disease-burden-and-mortality/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology